Through the program, a physician is able to collect a patient’s DNA sample using a cheek swab. The RxMatch Comprehensive Panel then analyzes 97 genes from the DNA sample to determine how a patient will likely respond to various medications, including opioids, statins, immunosuppressants and antidepressants. Physicians can use the panel’s results to guide appropriate dosage and prescriptions.
The program falls under the umbrella of pharmacogenomics, or the study of how genetics affect a patient’s response to medication.
“The objective of this project is to provide the most comprehensive and evidence-based information to the physician, thus decreasing the amount of time and money spent to achieve the correct medication,” David Loughmiller, laboratory manager for Intermountain Precision Genomics, said in a May 8 statement.
More articles on data analytics & precision medicine:
Geisinger to integrate DNA sequencing into routine clinical care
4 things to know about the national ‘All of Us’ biobank at Mayo Clinic
UCSF Health, UChicago Medicine partner with Color to offer patients genetic tests
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
